Overweight is a major public health issue, which affects conspicuous portion of the world population. It constitutes a risk factor for metabolic events that predispose an individual to diabetes, hypertensions and atherosclerosis. Overweight has been recently linked to low grade chronic inflammatory diseases, like type 2 diabetes, cardiovascular disease and cancer. However, acute inflammatory responses are important for defensive and homeostatic mechanisms of healing, repair and tissue regeneration1. Chronic inflammatory conditions include hypertension, diabetes, cardiovascular disorders (CVDs) and cancer2. A report by World Health Organization (WHO) in 2016 showed that over 1.9 billion adults above 18 were overweight worldwide, and 650 million adults were obese. These figures show, that 39 % of adults ≥ 18 years of age (representing 40 % women and 39 % men) were overweight, while 13 % of world adult population (representing 15 % women and 11 % men) were obese. Thus, from 1975 to 20163, the global prevalence of overweight and obesity cases has nearly tripled. Epidemiological evidence and clinical studies have clearly demonstrated, that overweight predisposed an individual to an increased incidence of thrombotic occlusion, or atherosclerosis that correlated with epicardial fat thickness4 and visceral obesity5. Endothelial dysfunction, monocytes recruitment, inflammation and platelet activation are associated with dyslipidemia. Studies showed that leptin resistance could be a possible candidate that links obesity with cardiovascular diseases6,7,8. Meta-analysis data by Coronary Heart Prevention of West Scotland Studies suggested, that leptin could induce CHD independently9. Although, leptin receptor (ObRb) on platelet membrane can signal angiogenesis, regulate bone formation, accelerate vascular endothelial injuries and further enhance platelet aggregation via platelet leptin receptor10,11 (Figure 1).

Figure 1

Activated platelet releases cytokines, chemokines, hemostatic factor, adhesion protein, antigen receptor, mitogens and platelet miRNA12. Platelet miRNA gene expression pattern has been demonstrated to be more accurate and precise, compared to mRNA expression pattern in differentiation and characterizing various diseases (such as atherosclerosis, myocardial infarction and cancers 13). Thus, this review article describes the relationship between overweight, leptin resistance, platelet activation and platelets miRNAs expression profiling, as well as to advocates the usefulness of miRNAs as predictive biomarkers of CAD in healthy overweight subjects.

Overweight can be referred as a leptin resistance condition. Leptin is a product of adiponectin from ob gene14, that signals the energy stores level via receptor in central nervous system. Leptin regulatesactivity of the hypothalamic nuclei, responsible for appetite and energy homeostasis. This hormone is anti-overweight, with its level decreasing during fasting and increasing after overfeeding in order to maintain energy status. Thus, leptin resistance in overweight subjects may signify the relationship between leptin concentration and overweight15. Multiple evidences have demonstrated that this hormone could engage in many pathophysiological pathways that could result in leptin resistance in different cells, arterial thrombosis formation16, platelet activation and aggregation17, arterial hypertension18 and vascular response to inflammation19,20. Other studies have shown that leptin is a prognosticator of atherosclerosis, myocardial infarction, stroke and coronary artery episode which is independent of body fat21.

The overall ability of this hormone to increase human platelet activation has been suggested in OB/OB mice and healthy control subjects11,21. However, Ozata et al. did not observe leptin on epinephrine, collagen and ADP platelet activation in both obese and overweight healthy subjects, and in leptin-deficient individuals22. Therefore, the notion of presence of leptin receptor on platelet membrane, signaling the prothrombotic episode of leptin resistance is still controversial. However, the association between platelet activation in overweight/obesity with dyslipidemia and endothelial dysfunction, triggers human platelet activation and aggregation, thus further enhancing the risk of atherosclerosis events23. Furthermore, studies have shown that obesity triggers platelet activation via release of an inflammatory mediator that activates multiple internal signaling networks, including platelet miRNA24. The role of miRNA (miR) on leptin resistance has been demonstrated in several gene expression profiles. MiRNA plays a modulation role in different metabolites. Thus, the exact effect of platelet miRNA on leptin in hypothalamic center remains elusive. The up-regulation of miR-200b and miR-200a were observed in hypothalamus center of obese-deficient ob/ob mice, and down-regulation of miR-200b and miR-200a were reported after leptin treatment in the hypothalamus25. Reduced level of miR-200b and miR-200a in the hypothalamic center induced the expression of both insulin and leptin receptors that signal the reduction of fat deposit and further restored insulin function in the liver 26. These miRNAs were present in activated platelets, suggesting that up regulation of miR-200a and miR-200b from activated platelets in overweight/obesity was altered (Table 1). Such alteration influenced leptin and insulin receptor signaling pathways in the hypothalamic nuclei25 which could serve as a target for therapeutic intervention in obesity/overweight individuals.

Platelets are made up of three secretory granules: the α-granules, lysosomes and dense granules27. The content of these granules is released into plasma after platelet activation, which may enhance and promote elevation levels of pro-atherogenic proteins. This includes growth factors (TGF-β, PDGF, bFGF and EGF), adhesion proteins (fibronectin, fibrinogen, P-selectin, thrombospondin, vWF, vitronectin, receptor complex glycoproteinIba-V-IX (GPIba-V-IX,), collagen receptor GP VI and GPIIb-IIIa), epithelial neutrophil activating protein 78 (ENA-78), chemokines CXC chemokine ligand 4 (CXCL4), RANTES (CCL5), platelet factor 4 (PF4), coagulation factors (factor V, XI, XIII), α2-antiplasmin, PAI-1 (plasminogen activator inhibitor), TFPI (tissue factor pathway inhibitor), protein S, antithrombin, plasminogen, cytokine-like factors (CD40L, β-thromboglobulin and IL-1β) and miRNA28 (Figure 2).

Figure 2

MiRNAs are a short class of non-coding endogenous RNAs, that post-regulate gene expression transcriptionally via either translational mRNA degradation, or repression. MiRNAs play crucial roles in controlling biochemical functions and mechanisms of different types of cells, including cell differentiation, developmental timing, tumorigenesis, proliferation, apoptosis as well as thrombosis and platelet functions. Similarly, miRNA itself as a regulatory element, is coordinatively modulated by multifarious effectors when carrying out basic functions, such as miRNA editing, single-nucleotide polymorphism, circadian clock and methylation. Platelet miRNAs act together in order to fine-tune and regulate a wide variety of this molecules in form of mRNA in different cellular functions. Those include aggregation, cell adhesion, proliferation, activation, chemotaxis, coagulation, proteolysis and cell survival. During these events, the mRNA is synthesized from DNA transcription and further translated into protein. Certain specific regions of these mRNA molecules are not normally translated into proteins. These regions include the 5′ untranslated region (5’ UTR), 5′ cap, poly-A tail and 3′ untranslated region (3' UTR). 3′ UTR often contains regulatory site that influences and regulates the post-transcriptional gene expression profiling29. Britton and Davidson, (1969)30 postulated that "activator" mRNA transcript may work to turn on and off genes as predicted by Watson-Crick base pairing to region, located within genes31. Three major forms of sRNAs regulation in plants and animals were identified, which include small interfering RNAs (siRNA), miRNAs (miRNA) and piwi-interacting RNAs (piRNA). Landry et al., 200932 found, that the platelet miRNA was not usually translated into protein, but it regulated mRNA by annealing to the recognition site on 3’ UTR of mRNA, coding gene sequence of 2-8 nucleotide, complementary to miRNA seed region33. This pairing was based on Watson-Crick nucleotide base pairing, such as miRNA-mRNA. The hybridization of these complexes does not require full complementary homology34 and complete homolog usually leads to degradation of a target mRNA, while partial pairing homology is a translational repression. Therefore, miRNA influences degradation to regulate mRNA by switching the functional gene transcript on and off, while translational repression of miRNA regulates the function of the protein expression34,35. This functional role of miRNA presumes a wide range of miRNA-mRNA interactions, following either convergent (many miRNA-Single targets), or divergent (single miRNA-many target mRNA) interaction. This results in robust pathways that regulate the synthesis of protein in a cell35.

Currently, the nature and extent of the involvement of platelet miRNAs in a non-(protein)-coding ribonucleic acids (RNAs) in physiology and pathological processes (in both plant and animals) has become clearer35. More than 280 miRNAs have been recognized and characterized from human nucleated platelets31,35. The miRNAs biosynthesis in biological systems is strictly regulated.

The biogenesis of platelet miRNAs began with transcription of the gene in non-coding region of miRNA using RNAs poly-III from the genome of megakaryocytes, harboring miRNA gene in either intergenic or intronic at promoter site. The first primary miRNA as a non-coding transcript is known as pri-miRNA, which acts upon by RNA poly III (called “Drosha”), that bounds to the microprocessor subunits DGCR-8 (di-george syndrome critical region-8) to produce a small length hairpin called pre-miRNA stemloop with 80-110 nucleotides base in length. Exporting-5 assists the nuclear export of pre-miRNA into the cytoplasm36. The presence of pre-miRNAs in the cellular cytoplasm is identified by ribonuclease (RNase) or Dicer enzymes which is a part of transactivation response binding protein (TRBP) complex. The complex Dicer/TRBP cleaves the pre-miRNAs loop to release a short length of double stranded miRNA, such as miRNA/miRNA, * or duplex37. The duplex (such as miRNA/miRNA) are transported into the RNA Induced Silencing Complex (RISC)38,39 and Helicase enzymes are used to unwind the double stranded miRNA into a single 22 nucleotides base, which is released as matured miRNA. The 2^nd strand miRNA, known as passenger strand is thought to be digested by the RISC complex substrate. Argonauts (Ago) protein family will assemble in RISC and provide stability and protection to the mature miRNA strand against RNase enzymes activities and will further guide the matured miRNA to its target 3′-untranslated region (UTR) of mRNA transcripts40 (Figure 3 ). However, the inverse modulation of platelet miRNA profiling during adipose tissue development in overweight and obesity is important for understanding miRNA dysregulation in adipose tissue of both obese humans and mice. Such modulation enhances chronic inflammation observed in obesity subject with insulin resistance41. Thus, a single nucleotide base change of mature and pre-miRNA may drive the emerging of new miRNA by influencing the biological function of these cells40.

Figure 3

The mutations or single-nucleotide polymorphism (SNP) that occur in the biogenesis of both mRNA and miRNA can be classified as follows:

(1) Mutations, that affect biogenesis enzymes of miRNA, or the promoter region of mRNA.

(2) Mutations, that affect the 3’ UTR region of the mRNA.

(3) Mutations that affect the miRNA seed region.42

SNP in the processing regions can be categorized as pri-miRNA, pre-miRNA, mature miRNA sequences and mRNA biogenesis machinery (promoter region). In fact, gene variations may influence either miRNA hairpin and biogenesis proteins, or enzymes in the processing accuracy43.

SNP in the seed region of miRNA may reduce the binding strength between miRNA and mRNA target sites, which will influence hundreds of gene expressions44.

Approximately 180,000 mutations or SNP found within the 3' UTR region mRNA were demonstrated with its corresponding mature miRNA 2,600 sequences. These were found in database sequence45. Mutations in the seed region of miRNA and 3’ UTR region of mRNA are almost identical in terms of variations and regulation of miRNA-mRNA* complex, affecting functions and disease vulnerability42. However, further molecular mechanism underlying disease-associated with 3’ UTR SNPs in mRNA still require further investigation46. For example, SNP meta-analysis of 8,120 patients and 8,364 controls identified four different SNPs in the following miRNAs (miRNA-149, miRNA-196a2, miRNA-499 and miRNA-146a), which increased patients CAD vulnerability47. Other articles have demonstrated that miR-146a was upregulated in CAD 47,48 due to the change of G to C in pre-miRNA. That affected the expression of mature miRNA-146a in CAD patients49. That finding was confirmed by Wang et al. and showed, that C allele was greater than G allele in gene that predisposed individuals to CAD 50,51. However, in type 2 diabetes patients with ischemic stroke, the miR-146a was downregulated (Table 1) 52. Other abundant miRNAs found in platelets miRNA were miR-223 and miR-126. In addition, miR-223, miR-107, miR- 495, miR-96 and miR-200b were actively involved in various platelet functions, such as platelet release, adhesion and aggregation,53 as summarized in Table 2.

The fact of discovery of miRNA as a stable molecule in plasma and serum is surprising despite the level of RNase enzymes activities 54. The expression of miRNA in tissue, or organ-specific, and its release into the plasma in response to tissue injury is considered to be a potential biomarker for different diseases55. The hypothesis that miRNA in blood cells could be used as diagnostic parameter in different diseases was first postulated by Mitchell et al.. He showed, that miRNA remained highly stable in both plasma and serum even after prolonged storage at room temperature, or repeated cycles of freezing and thawing. For example, tumor-derived miRNA could easily be identified in plasma sample from cancer patient with standard laboratory procedure56,57,54. The diagnostic role of circulating miRNA has been evaluated not only in cancer, but also in other clinical disorders, such as hepatic disease58, heart failure59 and diabetes60. Few studies have claimed platelets in obesity and overweight healthy individuals as the culprit factor, responsible for coronary artery disease61. The application of specific platelet miRNAs as markers for platelet activation will be a marginal milestone in the history of this diet-related disorder.

Large scale studies, presented by Nagalla et al. and Landry et al. found, that thirty different platelet miRNAs modulate platelet and endothelial angiogenesis (angio-miRs)32,35. These miRNAs, (miR-21, miR-200, miR-210 and miR-126), are well known to play critical roles in the vessel and capillary formation. The regulation of angiogenesis by miRNA in the endothelial cell was confirmed, using Dicer-knockdown mice experiment, demonstrating the essential role of Dicer in miRNA biogenesis62,63. Furthermore, Dicer gene deletion was shown to cause early death of mice during the embryonic stage, due to impaired angiogenesis64. In addition, Dicer knockdown of vascular smooth muscle cells VSMC specific caused the late embryonic death due to internal bleeding65, suggesting that platelet miRNA was an integral part of vascular development. Therefore, clusters of miR-221 and miR-222 are the most abundant and well distributed miRNAs across these three cells(platelet, endothelial and VSMC)66,67. Both miR-221 and miR-222 function as pro-inflammatory inhibitor of angiotensin II and reversed leucocytes adhesion (in vivo and in vitro)68, suggesting a possible role of these miRNA clusters in CAD dysregulation. The endothelial-enriched miR-92a has been proposed as a possible therapeutic target after treatment with anti-miR-92a oligonucleotide.Such treatment improved the formation of blood vessel and recovery of cardiovascular disorder in acute myocardial infarction in mice67. MiR-143/145 is the most abundant miRNA found in VSCM and is well characterized as part of the same bi-cistronic cluster. These miRNAs target multiple mRNAs to influence VSCM differentiation and simultaneously reduce proliferation68. The delivery of miR-145 by lentiviral in endothelial and VSCM inhibits monocyte/macrophages recruitment and infiltration, thus reducing inflammation and limiting plaque formation. These results suggest a new therapeutic target in order to decrease atherosclerotic progression and increase plaque atrial stability69.

Previous reports showed that more than 80 different diseases were associated with dysregulation, or mutation in miRNAs70. The mechanisms of platelet activation in various thrombotic diseases were well established71. The accurate etiology of miRNA in activated platelet in overweight and obesity is not clear, but obesity is always a risk factor for atherothrombotic episodes71. Landry et al. 2009 demonstrated that the platelets and megakaryocyte miRNAs had 219 different types of miRNA in platelet expression patterns and profiles72. The authors observed three most abundant miRNAs in human platelets; miR-19a, let-7c, and miR-223. Binding of miRNA-223 to 3' UTR region of P2Y12 mRNA receptor in HEK293 cell line repressed P2Y12 gene and decreased the activities of both platelet and megakaryocyte. However, dysregulation of miRNA-233 was observed in hyperreactive platelet, leading to overexpression of miRNA-22373. Thus, miR-223, miR-197 and miR-126 were involved in platelet hyperreactive and endovascular inflammation, stretching the application of these miRNAs as predictive biomarkers for diagnosis of CAD (Table 1)73.

Table 1

Platelet miRNA	Disease	Group	Methods	Reference
↓mir-223	Diabetes mellitus type 2 patients without ischemic stroke	Human/7 diabetes, 8 control	qRT-PCR	52
↓miR942, ↓20a ↑miR146a-5p*	Acute coronary syndrome (NSTEMI)	Human/13 CAD, 13 non-	qRT- PCR	74
↑ miR127-3p ↓miR185-5p*	Acute coronary syndrome (STEMI)	Human/44 CAD, 22 non-CAD	qRT-PCR	75
↑miR454* ↑miR545:9.1↓ miR-12801*	Premature coronary artery disease	Human/12 premature CAD, 12 controls	Microarray confirmed by qRT-PCR	53
↑miR-144, ↓miR-146a*	Diabetes mellitus type 2 patients with ischemic stroke	HUMAN/6 ischemic stroke ,8 controls	Microarray qRT-PCR	52
↑miR340* ↑miR624*	Mature coronary artery disease	Human/40 CAD, 40 controls	Microarray Confirmed by qRT-PCR	53

NSTEM, Non Segment Elevation Myocardial Infarction; STEM, Segment Elevation Myocardial Infarction. * Shows the platelet miRNA marker of atherosclerosis

In 2013, Osman and Fälker discovered 281 transcripts, of which 228 were mature miRNAs and 53 were pre-miRNAs. Six miRNAs: miR-339-3 p, miR-15 a, miR-365, miR-495, miR-361-3 p and miR-98, were upregulated, or downregulated in hyperreactive platelets28. The level of expression pattern, or characteristic of miRNAs in platelets were associated with a procoagulant (such as thrombin stimulation). Nagalla et al., 2011 demonstrated that there were 284 miRNA transcripts in human platelets, by which 74 were differentially expressed, based on the platelet reactivity35. Seven miRNA expression profiles (miR-320b, miR-190, miR-320d, miR-19b, miR-34b, miR-320c and miR-320a) were shown to have a strong relationship with the degree of platelet response to adrenaline35. In fact, the most abundant expressed platelets miRNA is miR-223, followed by miR-126 57. Others were identified as miR-200b, miR-107, miR-96 and miR- 49553. All of these miRNAs were involved in platelet hyperreactivity (such as platelet activation, adhesion and aggregation, as summarized in Table 2).

Table 2

	Platelet miRNA	Target protein(mRNA)	Function	Pathophysiology	Implication	Ref
1.	miRNA-223	P2Y12 receptorfor ADP	Regulate platelet Hyperreactive	miRNA-233: Dysregulation of miRNA-233 will results in hyperreactive platelet, leading to upregulation miRNA-223↑	miR-223 and miR-197 are platelet activation miRNA involved in vascular inflammation and have been shown as markers in the diagnosis of CAD.	73,76
2.	miRNA-200b	cAMP-dependent PKA	Keep platelet in hyporeactive state	miRNA-200b: Dysregulation in obesity/overweight subjects lead to release of plate αlpha- and dense granules that harbor inflammatory molecules in platelet. miRNA-200b inhibits endothelial angiogenesis upregulates↑	Overexpression of miR-200b in platelet activation may be used as a diagnostic maker of CAD	77,78
3	miR-107	CLOCK/Bmal1	vWF gene is regulated by CLOCK/Bmal1 complex in normal physiological state	miRNA-107: Dysregulationincreased the plasma level of vWF↑	Association with a prothrombotic state that promote CAD	79
4.	Member of miR-17-92 cluster (miR-17)	Fibronectin	Fibronectin aids in the formation of stable arterial thrombi at the site of endothelialinjury	Inhibition of fibronectin by miR-17 leads to impeded platelet coagulation and wound healing and is downregulated ↓	miR-17-92 and its family were dysregulated in CAD	80,81
5	miR29a*/miR-409-3p* and fibrinogen	FGA, FGB,and FGG)	Fibrinogen functions as hemostatic plug formation,	miR-29 reduce the level of mRNA genes such as FGG, FGB and FGA. Dysregulation of these miRNAs has been linked with cardiac fibrosis ↓	miR-29 family are grouped with MI-regulated member	82,83
6.	miR-96 and miR-15	VAMP8	miR-96 and miR-15 regulate VAMP8.VAMP8 aids in platelet activation, secretion of α-granules and platelet function.	SNPs in the 3’ untranslated region ( UTR) of VAMP8 mRNA resulted in VMP8 mRNA dysregulation and is upregulated ↑	The consequencerisk of myocardial infarction	84
7.	miR-495	Kelch protein	Platelet activation uses Kelch protein for actin and filament organization during platelet function	KLHL5 mRNA is required for platelet activation and miR-495 regulates the Kelch-like protein at 3’ UTR region. Repression of this protein in megakroyocytes leads to platelet hyporeaction	?	85
	miR-126 present in both platelet and endothelial cell	VCAM-1	The target of miRNA-126 is VCAM mRNA, and the suppression of VCAM leads to decreasing infiltration of leucocytes into the vascular endothelial cell	Mutation of miR-126 resulted in the expression of TNF-α that stimulate VCAM-1 expression and increase leukocyte adherence to endothelial ↓	Promotes CAD	86,87
9	miR-210.	ephrina3 receptor (efna3) and Tyrosine protein and Phosphatase(ptp1b)	The repression of the two molecules (ptp1b and efna3) by miRNA-210 enhances angiogenic property and endothelial angiogenesis	Mutation lead to downregulation of miR-210↓	Angiogenesis after MI	88
	miR-21	Rho kinase, SPROYTY2, RhoB,BMPRII, SOD2 and PTEN	All possess anti-angiogenic functions..	Increased expression of miR-21 inhibits angiogenesis of endothelial cells by downregulating several pro-angiogenicmiR-21↑	Atherosclerosis, CAD, apoptosis and neoangiogenes	89,90,91

miRNA (miR), mRNA (messenger RNA), ↑: upregulation, ↓: down-regulation, CAD: Coronary ArteryDisease

Plé and colleagues in 2012 detected more than 492 different mature miRNA transcripts in active platelets74,75,92. A total of 15 novel miRNAs were identified from human platelet: miR-103, miR-140, miR-24, miR-185, miR-223, miR-23, miR-320, miR-25, miR-21, miR-26, miR-191, miR-423, miR-101, miR-199 and let-786. This finding suggested a possible relationship between the platelet activation and the miRNA modification, which may an induce agonist-specific platelet function.

Jeanine et al., 2014 also reported the expression profile of platelet miRNA in patients with acute coronary syndrome after a series of diagnostic investigations. In blood sample of STEMI patients, miR185-5p and miR186-5p were downregulated, while miR221-3p and miR127-3p were upregulated in platelets. On the other hand, in blood samples of NSTEMI patients, miR942 and miR20a-5p were downregulated, whereas miR146a-5p and miR483-5p were upregulated in platelets (Table 2)74. Thus, in body circulation, the pathophysiology of platelet miRNA can exhibit clear characteristic differences of expression profiling in various platelet disorders. This condition however is dangerous if urgent measure is not taken, since the risk of heart failure (HF) in such case is eminent. Patients with systolic heart failure were found to have different platelet miRNA expression profiles, as compared to control subjects56. Platelets miRNA-150 expression level decreased more than three-fold in blood platelets of patients with heart failure, secondary to atrial fibrillation (Table 2) 75.

In addition, the study, conducted by Duan et al., 2014 showed, that the expression of platelet miRNA-223 and miRNA-146a in patients with ischemic stroke and diabetes mellitus was significantly higher, compared to healthy donors. The expression level of these two platelet miRNAs was suggested to correlate with platelet activation (Table 2)52.

The gene expression and bioinformatic analysis procedures have become the state-of-the-art methods for diagnosing a number of human diseases. Several studies have reported different miRNA expression profiles in platelets. The application of these miRNAs for diagnostic purpose in overweight healthy subjects will be a milestone in the history of treatment of this diet-related disorder. Six notable candidates of platelet miRNAs have been discovered and proposed for diagnostic accuracy in CAD upregulation: ↑ miR483-5p* ↑ miR146a-5p* ↑miR340* ↑miR624*, ↑miR451* and ↑miR454*. Current modern diagnostic laboratory method for identification of coronary obstruction is still in its early stage. Nevertheless, current molecular medicine and diagnostic methods are capable to identify if an individual is predisposed to the illness. Platelet miRNA expression profile detection is associated with platelet hyperactivity and may serve as an important marker for prevention of coronary artery disease (CAD) in human overweight/obesity.

ADP: Adenosine diphosphate

BFGF: Basic Fibroblast Growth Factor

CAD: coronary artery disease

cAMP: cyclic adenosine monophosphate

CCL5: RANTES

CD40L: CD40 Ligand

CHD: Coronary heart disease

CVDs: cardiovascular disorders

CXC: Chemokines

CXCL4: Chemokine ligand 4

DAG: 1,2-diacylglycerol

DGCR 8: di-george syndrome critical region-8

DNA: Deoxyribonucleic Acid

EGF: Epidermal Growth Factor

ENA: 78- epithelial neutrophil activating protein 78

IL-1β: interleukin -1β

IP3: inositol 1,4,5 triphosphate.

miRNA: microRNA

mRNA: messenger RNA

NSTEM: Non Segment Elevation Myocardial Infarction;

ObRb: Leptin receptor

PAI-1: Plasminogen Activator Inhibitor,

PDGF: Platelet-derived growth factor

PF4: platelet factor 4

piRNA: piwi-interacting RNAs

PKC: protein kinase C

PLC: phospholipase C

RISC: RNA In-duced Silencing Complex

siRNA: small interfering RNAs

SNP: single-nucleotide polymorphism

STEM: Segment Elevation Myocardial Infarction

TFPI: tissue factor pathway inhibitor,

TGF-β: Transforming growth factor beta

TRBP: Transactivation Response Binding Protein

UTR: untranslated region

VAMP8: Vesicle-associated Membrane Protein 8

VCAM-1: Vascular Cell Adhesion Molecules-1

VSMC: Vascular Smooth Muscle Cells

vWF: von willbrand factor

WHO: World Health Organization

The author declares no conflict of interest regarding the article for publication.

Sabariah Md Noor: initiate the conception and technicality; Azrina Azlan, and Loh Su Peng: guide the article publication along with flow of idea and amending the figure respectively; Yakubu Abdulrahman: do the written and revision of the paper.

This work was supported by the Geran Putra IPS 957600 (Putra Grant Initiative) from Universiti Putra Malaysia (UPM).

Purkayastha S. Cai D. Neuroinflammatory basis of metabolic syndrome Mol Metab 2013 2 4 356 63 2212-8778 10.1016/j.molmet.2013.09.005 24327952 Heap G.A. van Heel D.A. The genetics of chronic inflammatory diseases Hum Mol Genet 2009 18 101 6 0964-6906 10.1093/hmg/ddp001 19297396 Obesity Update O.E. Obesity Update 2017 Diabetologe (Heidelb) 2017 13 5 331 41 1860-9716 10.1007/s11428-017-0241-7 Mazzoccoli G. Copetti M. Dagostino M.P. Grilli M. Fontana A. Pellegrini F. Epicardial adipose tissue and idiopathic deep venous thrombosis: an association study Atherosclerosis 2012 223 2 378 83 0021-9150 10.1016/j.atherosclerosis.2012.05.033 22748278 Vayá A. Martínez-Triguero M.L. España F. Todolí J.A. Bonet E. Corella D. The metabolic syndrome and its individual components: its association with venous thromboembolism in a Mediterranean population Metab Syndr Relat Disord 2011 9 3 197 201 1540-4196 10.1089/met.2010.0117 21352080 Werner N. Nickenig G. From fat fighter to risk factor: the zigzag trek of leptin Arterioscler Thromb Vasc Biol 2004 24 1 7 9 1079-5642 10.1161/01.ATV.0000110908.43721.ad 14707035 Sader S. Nian M. Liu P. Leptin: a novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy Circulation 2003 108 6 644 6 0009-7322 10.1161/01.CIR.0000081427.01306.7D 12912793 Yang R. Barouch L.A. Leptin signaling and obesity: cardiovascular consequences Circ Res 2007 101 6 545 59 0009-7330 10.1161/CIRCRESAHA.107.156596 17872473 Wallace A.M. McMahon A.D. Packard C.J. Kelly A. Shepherd J. Gaw A. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS) Circulation 2001 104 25 3052 6 0009-7322 10.1161/hc5001.101061 11748099 Nakata M. Yada T. Soejima N. Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor Diabetes 1999 48 2 426 9 0012-1797 10.2337/diabetes.48.2.426 10334326 Konstantinides S. Schäfer K. Koschnick S. Loskutoff D.J. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity J Clin Invest 2001 108 10 1533 40 0021-9738 10.1172/JCI13143 11714745 Mitchell A.J. Gray W.D. Hayek S.S. Ko Y.A. Thomas S. Rooney K. Platelets confound the measurement of extracellular miRNA in archived plasma Sci Rep 2016 6 September 32651 2045-2322 10.1038/srep32651 27623086 Edelstein L.C. Nagalla S. Bray P.F. MicroRNAs in Platelet Production and Activation MicroRNAs Med. 2013 2013 101 116 10.1002/9781118300312.ch7 Stern J.H. Rutkowski J.M. Scherer P.E. Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk Cell Metab 2016 23 5 770 84 1550-4131 10.1016/j.cmet.2016.04.011 27166942 Jr M.G. Leibel R.L. Seeley R.J. Schwartz M.W. Obesity and Leptin Resistance: Distinguishing Cause from Effect Trends Endocrinol Metab 2011 21 643 51 10.1016/j.tem.2010.08.002.Obesity Mantzoros C.S. Magkos F. Brinkoetter M. Sienkiewicz E. Dardeno T.A. Kim S.Y. Leptin in human physiology and pathophysiology Am J Physiol Endocrinol Metab 2011 301 4 567 84 0193-1849 10.1152/ajpendo.00315.2011 21791620 Elbatarny H.S. Maurice D.H. Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex Am J Physiol Endocrinol Metab 2005 289 4 695 702 0193-1849 10.1152/ajpendo.00125.2005 15886225 Bełtowski J. Role of leptin in blood pressure regulation and arterial hypertension J Hypertens 2006 24 5 789 801 0263-6352 10.1097/01.hjh.0000222743.06584.66 16612235 Paz-Filho G. Mastronardi C. Franco C.B. Wang K.B. Wong M.L. Licinio J. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications Arq Bras Endocrinol Metabol 2012 56 9 597 607 0004-2730 10.1590/S0004-27302012000900001 23329181 Allman M. Wallace M. Gaskin L. Rivera C.A. Leptin induces an inflammatory phenotype in lean Wistar rats Mediators Inflamm 2009 2009 738620 0962-9351 10.1155/2009/738620 20150963 Chen T.H. Lee C.J. Wang J.H. Hsu B.G. High Serum Leptin Level is Associated with Peripheral Artery Disease in Geriatric Individuals Int J Gerontol 2018 12 3 191 5 1873-9598 10.1016/j.ijge.2018.02.001 Ozata M. Avcu F. Durmus O. Yilmaz I. Ozdemir I.C. Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency Obes Res 2001 9 10 627 30 1071-7323 10.1038/oby.2001.82 11595779 Mao X. Ait-Aissa K. Lagrange J. Youcef G. Louis H. Hypertension, hypercoagulability and the metabolic syndrome: a cluster of risk factors for cardiovascular disease Biomed Mater Eng 2012 22 1-3 35 48 1878-3619 10.3233/BME-2012-0688 22766701 Xia L. Zeng Z. Tang W.H. The Role of Platelet Microparticle Associated microRNAs in Cellular Crosstalk Front. Cardiovasc. Med. 2018 5 29 10.3389/fcvm.2018.00029 Dou L. Zhao T. Wang L. Huang X. Jiao J. Gao D. miR-200s contribute to interleukin-6 (IL-6)-induced insulin resistance in hepatocytes J Biol Chem 2013 288 31 22596 606 0021-9258 10.1074/jbc.M112.423145 23798681 Benoit C. Ould-Hamouda H. Crepin D. Gertler A. Amar L. Taouis M. Early leptin blockade predisposes fat-fed rats to overweight and modifies hypothalamic microRNAs J Endocrinol 2013 218 1 35 47 0022-0795 10.1530/JOE-12-0561 23576026 Sharda A. Flaumenhaft R. The life cycle of platelet granules F1000 Res 2018 7 0 236 2046-1402 10.12688/f1000research.13283.1 29560259 Bijak M. Saluk J. Ponczek M.B. Nowak P. Wachowicz B. The synthesis of proteins in unnucleated blood platelets Postepy Hig Med Dosw 2013 506 672 679 24018431 http://www.phmd.pl/fulltxt.php?ICID=1059587 Patil V.S. Zhou R. Rana T.M. Gene regulation by non-coding RNAs Crit Rev Biochem Mol Biol 2014 49 1 16 32 1040-9238 10.3109/10409238.2013.844092 24164576 Britten R.J. Davidson E.H. Dike S. Gene Regulation for Higher Cells: A Theory Science 1969 165 3891 349 357 10.1126/science.165.3891.349 Ui-Tei K. Naito Y. Nishi K. Juni A. Saigo K. Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect Nucleic Acids Res 2008 36 22 7100 9 0305-1048 10.1093/nar/gkn902 18988625 Landry P. Plante I. Ouellet D.L. Perron M.P. Rousseau G. Provost P. Existence of a microRNA pathway in anucleate platelets Nat Struct Mol Biol 2009 16 9 961 6 1545-9993 10.1038/nsmb.1651 19668211 Small E.M. Olson E.N. Pervasive roles of microRNAs in cardiovascular biology Nature 2011 469 7330 336 42 0028-0836 10.1038/nature09783 21248840 Bartel D.P. MicroRNAs: target recognition and regulatory functions Cell 2009 136 2 215 33 0092-8674 10.1016/j.cell.2009.01.002 19167326 Nagalla S. Shaw C. Kong X. Kondkar A.A. Edelstein L.C. Ma L. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity Blood 2011 117 19 5189 97 0006-4971 10.1182/blood-2010-09-299719 21415270 Lund E. Güttinger S. Calado A. J.E. Dahlberg U. Kutay Nuclear export of microRNA precursors Science 2004 303 5654 95 98 Zamore P.D. Tuschl T. Sharp P.A. Bartel D.P. Phillip D. Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals Zamore Thomas Tuschl. 2000 101 25 33 10.1016/S0092-8674(00)80620-0 Preall J.B. He Z. Gorra J.M. Sontheimer E.J. Short interfering RNA strand selection is independent of dsRNA processing polarity during RNAi in Drosophila Curr Biol 2006 16 5 530 5 0960-9822 10.1016/j.cub.2006.01.061 16527750 Siomi H. Siomi M.C. On the road to reading the RNA-interference code Nature 2009 457 7228 396 404 0028-0836 10.1038/nature07754 19158785 Gregory R.I. Chendrimada T.P. Cooch N. Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing Cell 2005 123 4 631 40 0092-8674 10.1016/j.cell.2005.10.022 16271387 Xie H. Sun L. Lodish H.F. Targeting microRNAs in obesity Expert Opin Ther Targets 2009 13 10 1227 38 1472-8222 10.1517/14728220903190707 19650761 Moszyńska A. Gebert M. Collawn J.F. Bartoszewski R. SNPs in microRNA target sites and their potential role in human disease Open Biol 2017 7 4 170019 2046-2441 10.1098/rsob.170019 28381629 Zhang W. Wang L. Zhou P. Song G. Shen M. Gan S. Identification and analysis of genetic variations in pri-miRNAs expressed specifically or at a high level in sheep skeletal muscle PLoS One 2015 10 2 e0117327 1932-6203 10.1371/journal.pone.0117327 25699993 Króliczewski J. Sobolewska A. Lejnowski D. Collawn J.F. Bartoszewski R. microRNA single polynucleotide polymorphism influences on microRNA biogenesis and mRNA target specificity Gene 2018 640 66 72 0378-1119 10.1016/j.gene.2017.10.021 29032146 Schwerk J. Savan R. Translating the Untranslated Region J Immunol 2015 195 7 2963 71 0022-1767 10.4049/jimmunol.1500756 26386038 Vaishnavi V. Manikandan M. Munirajan A.K. Mining the 3\textquotesingleUTR of autism-implicated genes for SNPs perturbing microRNA regulation Genomics Proteomics Bioinformatics 2014 12 2 92 104 1672-0229 10.1016/j.gpb.2014.01.003 24747189 X.D. Xiong M. Cho X.P. Cai J. Cheng X. Jing J.M. Cen X. Liu X.L. Yang Y. Suh A common variant in pre-miR-146 is associated with coronary artery disease risk and its mature miRNA expression Mutat Res - Fundam Mol Mech Mutagen. 2014 761 15 20 10.1016/j.mrfmmm.2014.01.001 Wang Y. Wang X. Li Z. Chen L. Zhou L. Li C. Two single nucleotide polymorphisms (rs2431697 and rs2910164) of miR-146a are associated with risk of coronary artery disease Int J Environ Res Public Health 2017 14 5 4 10 1661-7827 10.3390/ijerph14050514 28489066 Liu X. You L. Zhou R. Zhang J. Significant association between functional microRNA polymorphisms and coronary heart disease susceptibility% UNKNOWN UNICODE CHARACTER 0202F (NARROW NO-BREAK SPACE) : a comprehensive meta-analysis involving 16484 subjects Oncotarget 2016 \textbullet\textbullet\textbullet 1 11 1949-2553 10.18632/oncotarget.14249 28035059 Xie X. Shi X. Xun X. Rao L. Association between microRNA polymorphisms and coronary heart disease : A meta-analysis Herz 2017 42 6 593 603 0340-9937 10.1007/s00059-016-4495-4 27832287 Bao M.H. Xiao Y. Zhang Q.S. Luo H.Q. Luo J. Zhao J. Meta-analysis of miR-146a polymorphisms association with coronary artery diseases and ischemic stroke Int J Mol Sci 2015 16 7 14305 17 1661-6596 10.3390/ijms160714305 26114385 Duan X. Zhan Q. Song B. Zeng S. Zhou J. Long Y. Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke J Diabetes Complications 2014 28 5 705 10 1056-8727 10.1016/j.jdiacomp.2014.04.012 24908639 Gatsiou A. Boeckel J.N. Randriamboavonjy V. Stellos K. MicroRNAs in platelet biogenesis and function: implications in vascular homeostasis and inflammation Curr Vasc Pharmacol 2012 10 5 524 31 1570-1611 10.2174/157016112801784611 22338566 Mitchell P.S. Parkin R.K. Kroh E.M. Circulating microRNAs as stable blood-based markers for cancer detection Proceedings of the National Academy of Sciences 2008 105 30 10513 10518 10.1073/pnas.0804549105 Laterza O.F. Lim L. Garrett-Engele P.W. Vlasakova K. Muniappa N. Tanaka W.K. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury Clin Chem 2009 55 11 1977 83 0009-9147 10.1373/clinchem.2009.131797 19745058 Schulte C. Zeller T. microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts Cardiovasc Diagn Ther 2015 5 1 17 36 2223-3652 10.3978/j.issn.2223-3652.2014.12.03 25774345 Pordzik J. Pisarz K. De Rosa S. Jones A.D. Eyileten C. Indolfi C. The potential role of platelet-related microRNAs in the development of cardiovascular events in high-risk populations, including diabetic patients: A review Front Endocrinol (Lausanne) 2018 9 MAR 74 1664-2392 10.3389/fendo.2018.00074 29615970 Ding X. Ding J. Ning J. Yi F. Chen J. Zhao D. Circulating microRNA-122 as a potential biomarker for liver injury Mol Med Rep 2012 5 6 1428 32 1791-2997 10.3892/mmr.2012.838 22427142 Tijsen A.J. Creemers E.E. Moerland P.D. de Windt L.J. van der Wal A.C. Kok W.E. MiR423-5p as a circulating biomarker for heart failure Circ Res 2010 106 6 1035 9 0009-7330 10.1161/CIRCRESAHA.110.218297 20185794 S. Yang J. Zhao Y. Chen M. Lei Biomarkers Associated with Ischemic Stroke in Diabetes Mellitus Patients Cardiovascular toxicology 2016 16 3 213 222 Santilli F. Vazzana N. Liani R. Guagnano M.T. Dav\`\i G. Platelet activation in obesity and metabolic syndrome Obes Rev 2012 13 1 27 42 1467-7881 10.1111/j.1467-789X.2011.00930.x 21917110 F. Santilli N. Vazzana R. Liani M. Guagnano G. Davì Platelet activation in obesity and metabolic syndrome. . doi: Obes Rev. 2012 13 1 27 42 10.1111/j.1467-789X.2011.00930.x Yang W.J. Yang D.D. Na S. Sandusky G.E. Zhang Q. Zhao G. Dicer Is Required for Embryonic Angiogenesis during Mouse Development Journal of Biological Chemistry 2005 280 1 9330 9335 10.1074/jbc.M413394200 Duan R. Pak C. Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA Human molecular genetics 2007 16 9 1124 1131 10.1093/hmg/ddm062 Albinsson S. Suarez Y. Skoura A. Offermanns S. Joseph M. Sessa W.C. differentiation and function 2011 30 6 1118 1126 10.1161/ATVBAHA.109.200873.miRNAs Altuvia Y. Landgraf P. Lithwick G. Elefant N. Pfeffer S. Aravin A. Clustering and conservation patterns of human microRNAs Nucleic Acids Res 2005 33 8 2697 706 0305-1048 10.1093/nar/gki567 15891114 Zhu N. Zhang D. Chen S. Liu X. Lin L. Huang X. Endothelial enriched microRNAs regulate angiotensin II-induced endothelial inflammation and migration Atherosclerosis 2011 215 2 286 93 0021-9150 10.1016/j.atherosclerosis.2010.12.024 21310411 Hartmann D. Thum T. MicroRNAs and vascular (dys)function Vascul Pharmacol 2011 55 4 92 105 1537-1891 10.1016/j.vph.2011.07.005 21802526 Lovren F. Pan Y. Quan A. Singh K.K. Shukla P.C. Gupta N. MicroRNA-145 targeted therapy reduces atherosclerosis Circulation 2012 126 11 81 90 0009-7322 10.1161/CIRCULATIONAHA.111.084186 22965997 Lu M. Zhang Q. Deng M. Miao J. Guo Y. Gao W. An analysis of human microRNA and disease associations PLoS One 2008 3 10 e3420 1932-6203 10.1371/journal.pone.0003420 18923704 Nieuwdorp M. Stroes E.S.G. Meijers J.C.M. Büller H. Hypercoagulability in the metabolic syndrome Curr Opin Pharmacol. 2005 5 2 Spec. Iss 155 159 10.1016/j.coph.2004.10.003 Zimmerman G.a. A.S. Weyrich Pathways to Altered Phenotype and Function Arterioscler Thromb 2008 28 3 1049-8834 10.1161/ATVBAHA.107.160218.Signal-Dependent Schulte C. Molz S. Appelbaum S. Karakas M. Ojeda F. Lau D.M. MiRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease PLoS One 2015 10 12 e0145930 1932-6203 10.1371/journal.pone.0145930 26720041 Goren Y. Meiri E. Hogan C. Mitchell H. Lebanony D. Salman N. Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure Am J Cardiol 2014 113 6 976 81 0002-9149 10.1016/j.amjcard.2013.11.060 24462065 JA Ward N Esa R Pidikiti JE Freedman JF Keaney K Tanriverdi O Vitseva V Ambros R Lee DD McManus Circulating cell and plasma microRNA profiles differ between non-ST-segment and ST-segment-elevation myocardial infarction Family medicine & medical science research 2014 2 2 108 10.4172/2327-4972.1000108 Hollopeter G. Jantzen H.M. Vincent D. Li G. England L. Ramakrishnan V. Identification of the platelet ADP receptor targeted by antithrombotic drugs Nature 2001 409 6817 202 7 0028-0836 10.1038/35051599 11196645 Cavarretta E. Chiariello G.A. Condorelli G. Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra Eur Heart J 2013 34 44 3400 2 0195-668X 10.1093/eurheartj/eht032 23391580 Somanath P.R. Podrez E.A. Chen J. Ma Y.I. Antoch M. Byzova T.V. Deficiency in core circadian protein Bmal1 is associated with a prothrombotic and vascular phenotype Journal of cellular physiology 2011 226 1 132 40 0092-8674 10.1002/jcp.22314.Deficiency Shan S.W. Lee D.Y. Deng Z. Shatseva T. Jeyapalan Z. Du W.W. MicroRNA MiR-17 retards tissue growth and represses fibronectin expression Nat Cell Biol 2009 11 8 1031 8 1465-7392 10.1038/ncb1917 19633662 Fichtlscherer S. De Rosa S. Fox H. Schwietz T. Fischer A. Liebetrau C. Circulating microRNAs in patients with coronary artery disease Circ Res 2010 107 5 677 84 0009-7330 10.1161/CIRCRESAHA.109.215566 20595655 Peng H. Zhong M. Zhao W. Wang C. Zhang J. Liu X. Urinary miR-29 correlates with albuminuria and carotid intima-media thickness in type 2 diabetes patients PLoS One 2013 8 12 e82607 1932-6203 10.1371/journal.pone.0082607 24349318 van Rooij E. Sutherland L.B. Thatcher J.E. DiMaio J.M. Naseem R.H. Marshall W.S. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis Proc Natl Acad Sci USA 2008 105 35 13027 32 0027-8424 10.1073/pnas.0805038105 18723672 Shiffman D. Rowland C.M. Louie J.Z. Luke M.M. Bare L.A. Bolonick J.I. Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction Arterioscler Thromb Vasc Biol 2006 26 7 1613 8 1079-5642 10.1161/01.ATV.0000226543.77214.e4 16690874 Ezzell R.M. Kenney D.M. Egan S. Stossel T.P. Hartwig J.H. Localization of the domain of actin-binding protein that binds to membrane glycoprotein Ib and actin in human platelets J Biol Chem 1988 263 26 13303 9 0021-9258 3138234 Elgheznawy A. Fleming I. Platelet-enriched microRNAs and cardiovascular homeostasis Antioxid Redox Signal 2017 2017 9 10.1089/ars.2017.7289 Harris T.A. Yamakuchi M. Ferlito M. Mendell J.T. Lowenstein C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1 Proc Natl Acad Sci USA 2008 105 5 1516 21 10.1073/pnas.0707493105 18227515 Gambaryan S. Kobsar A. Rukoyatkina N. Herterich S. Geiger J. Smolenski A. Thrombin and collagen induce a feedback inhibitory signaling pathway in platelets involving dissociation of the catalytic subunit of protein kinase A from an NFkappaB-IkappaB complex J Biol Chem 2010 285 24 18352 63 0021-9258 10.1074/jbc.M109.077602 20356841 Choi Y.C. Yoon S. Jeong Y. Yoon J. Baek K. Regulation of vascular endothelial growth factor signaling by miR-200b Mol Cells 2011 32 1 77 82 1016-8478 10.1007/s10059-011-1042-2 21544626 Fasanaro P. D'Alessandra Y. Di Stefano V. Melchionna R. Romani S. Pompilio G. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3 J Biol Chem 2008 283 23 15878 83 0021-9258 10.1074/jbc.M800731200 18417479 Guduric-Fuchs J. O'Connor A. Cullen A. Harwood L. Medina R.J. O'Neill C.L. Deep sequencing reveals predominant expression of miR-21 amongst the small non-coding RNAs in retinal microvascular endothelial cells J Cell Biochem 2012 113 6 2098 111 0730-2312 10.1002/jcb.24084 22298343 Fleissner F. Jazbutyte V. Fiedler J. Gupta S.K. Yin X. Xu Q. Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism Circ Res 2010 107 1 138 43 0009-7330 10.1161/CIRCRESAHA.110.216770 20489163 Plé H. Landry P. Benham A. Coarfa C. Gunaratne P.H. Provost P. The repertoire and features of human platelet microRNAs PLoS One 2012 7 12 e50746 1932-6203 10.1371/journal.pone.0050746 23226537